Carole Ben-Maimon

Carole Ben-Maimon, M.D. previously served as president of Global Pharmaceuticals, Impax Laboratories generic pharmaceutical division. In this role, Dr. Ben-Maimon reported to Impax's president and chief executive officer and was responsible for expanding Impax's generic business by growing capability in the U.S. market while driving global opportunities through partnerships and actively exploring M & A opportunities. Prior to Impax, Dr. Ben-Maimon enjoyed a broad base of executive experience in the pharmaceutical industry. She was senior vice president, a corporate strategy consulting to the president, chief executive officer, and investors at Qualitest Pharmaceuticals, Inc. Prior to her role at Qualitest, she held executive positions with Barr Pharmaceuticals, including president and chief operating officer of Duramed Research (formerly known as Barr Research), a subsidiary of Barr Pharmaceuticals Inc. and with Teva Pharmaceuticals USA where she was senior vice president, Science and Public Policy. From 1996 to 2000, she served as senior vice president, Research and Development at Teva. She has also served as president and chief executive officer of Alita Pharmaceuticals, Inc. - a company which she founded. She served as the chairman of the board of the Generic Pharmaceutical Association from 2000 to 2003 and is also a published author of numerous scientific and clinical articles. Dr. Ben-Maimon is a graduate of Thomas Jefferson Medical College and received a bachelor of arts in biology from The University of Pennsylvania where she graduated magna cum laude. She is board certified in internal medicine and completed clinical and research training in nephrology at Thomas Jefferson University.